Menu
GWAS Study

Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia.

Ruderfer DM, Fanous AH, Ripke S et al.

24280982 PubMed ID
GWAS Study Type
39202 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

RD
Ruderfer DM
FA
Fanous AH
RS
Ripke S
MA
McQuillin A
AR
Amdur RL
GP
Gejman PV
OM
O'Donovan MC
AO
Andreassen OA
DS
Djurovic S
HC
Hultman CM
KJ
Kelsoe JR
JS
Jamain S
LM
Landén M
LM
Leboyer M
NV
Nimgaonkar V
NJ
Nurnberger J
SJ
Smoller JW
CN
Craddock N
CA
Corvin A
SP
Sullivan PF
HP
Holmans P
SP
Sklar P
KK
Kendler KS
Chapter II

Abstract

Summary of the research findings

Bipolar disorder and schizophrenia are two often severe disorders with high heritabilities. Recent studies have demonstrated a large overlap of genetic risk loci between these disorders but diagnostic and molecular distinctions still remain. Here, we perform a combined genome-wide association study (GWAS) of 19 779 bipolar disorder (BP) and schizophrenia (SCZ) cases versus 19 423 controls, in addition to a direct comparison GWAS of 7129 SCZ cases versus 9252 BP cases. In our case-control analysis, we identify five previously identified regions reaching genome-wide significance (CACNA1C, IFI44L, MHC, TRANK1 and MAD1L1) and a novel locus near PIK3C2A. We create a polygenic risk score that is significantly different between BP and SCZ and show a significant correlation between a BP polygenic risk score and the clinical dimension of mania in SCZ patients. Our results indicate that first, combining diseases with similar genetic risk profiles improves power to detect shared risk loci and second, that future direct comparisons of BP and SCZ are likely to identify loci with significant differential effects. Identifying these loci should aid in the fundamental understanding of how these diseases differ biologically. These findings also indicate that combining clinical symptom dimensions and polygenic signatures could provide additional information that may someday be used clinically.

Up to 4,528 European ancestry schizophrenia cases, up to 4,841 schizophrenia cases, up to 7,362 European ancestry bipolar disorder cases, up to 3,048 bipolar disorder cases, up to 11,637 European ancestry controls, up to 7,786 controls

Chapter III

Study Statistics

Key metrics and study information

39202
Total Participants
GWAS
Study Type
No
Replicated
European, NR, European
Ancestry
Sweden, U.S., Germany, U.K., Republic of Ireland, Norway, Denmark, Bulgaria, Netherlands, Portugal, France, Australia, Canada
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.